Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
종목 코드 ARCT
회사 이름Arcturus Therapeutics Holdings Inc
상장일May 22, 2013
CEOPayne (Joseph E)
직원 수174
유형Ordinary Share
회계 연도 종료May 22
주소10285 Science Center Drive
도시SAN DIEGO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호92121-1132
전화18589002660
웹사이트https://arcturusrx.com/
종목 코드 ARCT
상장일May 22, 2013
CEOPayne (Joseph E)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음